Immunomedics, Inc. (NASDAQ:IMMU) has a beta value of 3.33 and has seen 7,330,337 shares traded in the recent trading session. The company, currently valued at $19.56 Billion, closed the recent trade at $84.58 per share which meant it gained $0.93 on the day or 1.11% during that session. The IMMU stock price is -2.75% off its 52-week high price of $86.91 and 89.6% above the 52-week low of $8.8. If we look at the company’s 10-day average daily trading volume, we find that it stood at 17.35 Million shares traded. The 3-month trading volume is 3.76 Million shares.
The consensus among analysts is that Immunomedics, Inc. (IMMU) is an Overweight stock at the moment, with a recommendation rating of 1.8. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 5 out of 8 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.25.
Immunomedics, Inc. (NASDAQ:IMMU) trade information
Sporting 1.11% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Sep 14 when the IMMU stock price touched $86.91- or saw a rise of 2.68%. Year-to-date, Immunomedics, Inc. shares have moved 299.74%, while the 5-day performance has seen it change 108.8%. Over the past 30 days, the shares of Immunomedics, Inc. (NASDAQ:IMMU) have changed 111.46%. Short interest in the company has seen 26.03 Million shares shorted with days to cover at 6.92.
Wall Street analysts have a consensus price target for the stock at $72.51, which means that the shares’ value could jump -14.27% from current levels. The projected low price target is $47.6 while the price target rests at a high of $88. In that case, then, we find that the current price level is +4.04% off the targeted high while a plunge would see the stock lose -43.72% from current levels.
Immunomedics, Inc. (IMMU) estimates and forecasts
Figures show that Immunomedics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +782.38% over the past 6 months, with this year growth rate of -42.39%, compared to 13.7% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 49% and 70% for the next quarter. Revenue growth from the last financial year stood is estimated to be +42401.7%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -29.1% over the past 5 years. Earnings growth for 2020 is a modest -120.6% while over the next 5 years, the company’s earnings are expected to increase by 64.8%.
Immunomedics, Inc. (NASDAQ:IMMU)’s Major holders
Insiders own 0.14% of the company shares, while shares held by institutions stand at 81.31% with a share float percentage of 81.42%. Investors are also buoyed by the number of investors in a company, with Immunomedics, Inc. having a total of 327 institutions that hold shares in the company. The top two institutional holders are Avoro Capital Advisors LLC with over 26.25 Million shares worth more than $930.3 Million. As of June 29, 2020, Avoro Capital Advisors LLC held 11.36% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 18.86 Million shares as of June 29, 2020. The firm’s total holdings are worth over $668.54 Million and represent 8.16% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. As of June 29, 2020, the former fund manager holds about 2.56% shares in the company for having 5917467 shares of worth $209.72 Million while later fund manager owns 5.2 Million shares of worth $184.25 Million as of June 29, 2020, which makes it owner of about 2.25% of company’s outstanding stock.